SequelSEC

Vivos Therapeutics, Inc. VVOS

Surgical & Medical Instruments & Apparatus · CIK 0001716166 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$17.44M
Fiscal year ended 2025-12-31
Operating income
-$19.89M
Fiscal year ended 2025-12-31
Free cash flow
-$17.60M
Fiscal year ended 2025-12-31

Vivos Therapeutics, Inc. (VVOS) reported revenue of $17.44M and net income of -$21.17M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Vivos Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Vivos Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$17.44M$15.03M$13.80M$16.02M$16.88M$13.07M$11.39M
Cost of revenue$6.90M$6.01M$5.53MUnavailableUnavailableUnavailableUnavailable
Gross profit$10.54M$9.02M$8.27MUnavailableUnavailableUnavailable$8.66M
Operating income-$19.89M-$11.17M-$17.30M-$25.03M-$20.38M-$12.04M-$10.58M
Net income-$21.17M-$11.14M-$13.58M-$23.84M-$20.29M-$12.06M-$10.75M
Research & development$100.00K$100.00K$100.00K$200.00K$200.00KUnavailableUnavailable
Weighted-average diluted sharesshares 10.27Mshares 5.02Mshares 1.22MUnavailableUnavailableUnavailableUnavailable
Pretax income-$21.23M-$11.14M-$13.58M-$23.84M-$20.29M-$12.06M-$10.75M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.07$-2.22$-11.14$-25.90UnavailableUnavailableUnavailable
Selling, general & administrative$29.13M$19.61M$24.95M$34.38M$31.34M$18.40M$18.48M
General & administrative$27.73M$17.88M$22.48M$29.04M$25.79M$16.09M$16.17M
Selling & marketing$1.40M$1.73M$2.47M$5.34M$5.55M$2.31M$2.31M

Balance

Vivos Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$2.03M$6.26M$1.64M$3.52M$24.03M$18.21M$469.35K
Total assets$25.15M$15.28M$10.73M$13.72M$33.69M$25.33M$7.55M
Current assets$4.38M$7.47M$2.46M$5.42M$27.32M$20.39M$1.98M
Total liabilities$26.70M$7.33M$10.32M$8.92M$8.15M$8.41M$9.18M
Current liabilities$18.08M$4.98M$7.29M$6.81M$7.51M$7.84M$9.09M
Total equity incl. NCI-$1.55M$7.95M$411.00K$4.80M$25.54M$16.92M-$2.94M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.32M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$1.58M$430.00K$202.00K$457.00K$1.20M$1.43M$871.29K
Goodwill$8.57M$2.84M$2.84M$2.84M$2.84M$2.67M$2.67M
Long-term debt$469.00K$1.20M$1.20MUnavailable$1.26M$423.00K$3.71M
Accounts payable$1.68M$1.10M$2.14M$1.41M$920.00K$781.00K$1.08M

Cash flow

Vivos Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$15.26M-$12.69M-$11.95M-$19.59M-$15.74M-$5.68M-$5.34M
Capital expenditures$2.34M$568.00K$803.00K$924.00K$2.40M$120.00K$175.60K
Investing cash flow-$7.53M-$568.00K-$853.00K-$924.00K-$2.61M-$120.00K$86.22K
Financing cash flow$18.56M$17.88M$10.92MUnavailable$24.17M$23.54M$4.47M
Net change in cash-$4.23M$4.62M-$1.88M-$20.51M$5.82M$17.74M-$785.37K
Stock-based compensation$661.00K$762.00K$1.11M$2.40M$2.66M$2.17M$1.99M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.31M$581.00K$621.00K$669.00K$733.00K$718.00K$751.23K

Derived

Vivos Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$17.60M-$13.26M-$12.75M-$20.51M-$18.13M-$5.80M-$5.52M
Gross margin60.4%60.0%59.9%62.5%74.6%79.7%76.0%
Operating margin-114.1%-74.3%-125.3%-156.2%-120.7%-92.1%-92.8%
FCF margin-100.9%-88.2%-92.4%-128.0%-107.4%-44.4%-48.4%
SBC / revenue3.8%5.1%8.0%15.0%15.7%16.6%17.4%
Current ratio0.24x1.50x0.34x0.80x3.64x2.60x0.22x
Revenue YoY growth16.0%8.9%-13.9%-5.1%29.2%14.7%Unavailable
Net margin-121.4%-74.1%-98.4%-148.8%-120.2%-92.3%-94.4%
R&D / revenue0.6%0.7%0.7%1.2%1.2%UnavailableUnavailable
CapEx / revenue13.4%3.8%5.8%5.8%14.2%0.9%1.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VVOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2021-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2020-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.